[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Clarent Biopharma, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":92},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100647107","phase-2-oral-cbp-0276-or-placebo-in-adults-with-active-psoriatic-arthritis-psa-100647107",false,"NCT07706530","Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)","A Phase 2 Randomized, Double Blind, Clinical Trial (RCT) to Assess the Efficacy, Safety, and Tolerability of Oral CBP-0276 200mg QD, 800mg QD or Placebo for CBP-0276, Administered to Adults With Active Psoriatic Arthritis (PsA).","Inclusion Criteria:\n\n* Subject must voluntarily sign the informed consent form before any study-related procedures, understand and communicate with the investigator smoothly during the trial, and understand and voluntarily strictly abide by the provisions of this clinical study protocol;\n* Age ≥ 18 years and ≤ 75 years at the time of signing the informed consent form, male or female;\n* Body Mass Index (BMI) ≥ 18 and ≤ 39 kg\u002Fm2 at screening;\n* Fulfilled the 2006 Classification Criteria for Psoriatic Arthritis (CASPAR) and had symptoms of psoriatic arthritis for more than 6 months but less than 12 months of evolution at screening\n* Had active PsA before randomization (defined as ≥ 3\u002F68 tender joint count and ≥ 3\u002F66 swollen joint count);\n* Active plaque psoriasis (at least one plaque lesion) at screening, or a history of plaque psoriasis;\n* Failure to respond or stabilize on NSAIDs and\u002For csDMARDs (Inadequate Responders)\n* Female subjects of childbearing potential must have a negative pregnancy test during the screening period and prior to randomization.\n\nExclusion Criteria:\n\n* History of Drug-induced psoriasis (including, but not limited to, psoriasis induced by beta-blockers, calcium channel inhibitors, or lithium);\n* Had other active inflammatory diseases or autoimmune diseases other than psoriatic arthritis, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, reactive arthritis, inflammatory bowel disease arthritis, etc.;\n* History of organ transplantation (except for corneal transplantation within 3 months prior to screening;\n* History of lymphoproliferative disorders, including symptoms and signs of lymphoma or underlying lymphoproliferative disorders;\n* Had a serious infection (systemic infection, use of intravenous anti-infective therapy, or hospitalization due to infection) within 4 weeks prior to screening, or had an active or chronic infection at screening that the investigator considers unsuitable for inclusion in this trial;\n* History of severe opportunistic infections (including but not limited to Pneumocystis carinii pneumonia, coccidioidomycosis, etc.) or immunodeficiency disease;\n* History of invasive fungal infection;\n* Any active malignancy or history of malignancy within 5 years prior to screening, with the exception of cured squamous or basal cell carcinoma of the skin or in situ cervical cancer;\n* Joint surgery (including but not limited to meniscectomy, joint transplant, joint replacement, arthrodesis, etc.) within 8 weeks prior to screening; or the joint had not recovered after surgery (including but not limited to incision infection, unhealed wound, open drainage, etc.) at the time of screening;\n* Major surgery within 8 weeks prior to screening, or planned surgery during the study;\n* Had donated or lost ≥ 400 mL of blood within 8 weeks prior to randomization and\u002For planned to donate blood during the study;\n* History of moderate to severe congestive heart failure (New York Heart Association \\[NYHA\\] functional class ≥ III), cardiovascular events, or severe bleeding events within 3 months prior to screening;\n* Subjects with serious, progressive, uncontrolled cardiovascular and cerebrovascular diseases, liver, kidney, lung, gastrointestinal tract, hematopoietic system, endocrine system, nervous system diseases, or other conditions that the investigator considered unsuitable for this trial;\n* Subjects with a history of depression and\u002For active suicidal ideation as assessed by Sheehan-Suicidality Tracking Scale (S-STS) or any suicide attempt, suicidal behavior, or clinical judgment of the investigator to be at risk of suicide during the screening period were excluded;\n* Subjects with a history, symptoms and examination findings suggestive of active TB or latent TB at screening.\n* Positive test for hepatitis B, C, syphilis, or human immunodeficiency virus (HIV) antibody at screening;\n* Use of any of the following medications or participation in a clinical study (defined as signed informed consent): A) Use of any biologic drugs in the last 6 months, such as a TNF inhibitor within a specified time period prior to randomization (e.g., use of recombinant human tumor necrosis factor receptor-antibody fusion protein within 4 weeks prior to randomization; subjects who had received infliximab within 8 weeks before randomization; received adalimumab, golimumab, or certolizumab within 10 weeks before randomization); B) Had used at least 2 bDMARDs (including at least 2 different classes of TNF inhibitors) before randomization; C) Subjects who had used traditional synthetic disease-modifying antirheumatic drugs (csDMARDs) or systemic immunosuppressive agents (such as cyclophosphamide, cyclosporine, azathioprine, and mycophenolate mofetil) other than MTX, LEF, PDE-4 inhibitor, or SSZ within 4 weeks before randomization; D) Subjects who had received psoriatic arthritis or psoriasis herbal preparations patent medicines (such as Tripterygium wilfordii, total glucosides of peony, sinomenine, and kunxian) within 4 weeks before randomization; E) Had received any intra-articular injection therapy (such as glucocorticoids and hyaluronic acid) within 4 weeks before randomization; F) Phototherapy\u002Fphotochemotherapy (including psoralen and ultraviolet A (PUVA) phototherapy, ultraviolet B (UVB) within 4 weeks prior to randomization; G) Received topical psoriasis treatments\u002Fother systemic treatments within 4 weeks prior to randomization, such as topical corticosteroids, vitamin D3 derivatives, or retinoids; however, the following topical treatments were allowed: non-medical scalp lotions (i.e., without glucocorticoids or vitamin D3 derivatives, calcineurin inhibitors, etc.), mild emollients (without alpha or beta hydroxy acids, urea, salicylic acid); H) Oral, intravenous, or intramuscular glucocorticoids within 4 weeks prior to randomization; I) Prior exposure to anti-interleukin 17 (IL-17), anti-IL-17 receptor, anti-IL-12\u002FIL-23, and IL-23p19 agents; J) Used of other biologic agents for the treatment of psoriasis\u002Fpsoriatic arthritis within 6 months or 5 half-lives (whichever is longer) prior to randomization (including but not limited to, for example, anti-IL-6, anti-CD20 monoclonal antibody, CTLA4 antibody) or JAK inhibitor; K) Subjects who had used other clinical trial drugs, vaccines or medical devices or were expected to have residual effects of the trial treatment within 2 weeks or 5 half-lives (whichever is longer) before randomization (except for those who are clearly given placebo throughout the trial); L) Subjects who are allergic to the ingredients or excipients of the investigational product, or to other biological agents; M) Had received a live attenuated vaccine within 12 weeks prior to randomization, or planned to receive a live attenuated vaccine during the study, or within 20 weeks after the end of study treatment; or N) Had used strong opioid analgesics (such as methadone, morphine, hydromorphone, etc.) within 6 weeks prior to randomization.\n* Abnormal and clinically significant screening laboratory value that, in the opinion of the investigator, would pose an unacceptable risk to the subject if he or she participated in the study, or any of the following abnormalities as specified: A) Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP) ≥ 3x upper limit of normal (ULN); or total bilirubin or gamma-glutamyl transpeptidase (GT) ≥ 1.5 times the ULN; B) Serum creatinine ≥ 1.5 times ULN; C) Hemoglobin \\\u003C 85.0 g\u002FL for male subjects and \\\u003C 80.0 g\u002FL for female subjects; D) Total leukocyte count (WBC) \\\u003C 3.0 \\* 109\u002FL; E) Neutropenia (neutrophils \\\u003C 1.5 \\* 109\u002FL); or F) Thrombocytopenia (platelets \\\u003C 100 \\* 109\u002FL);\n* Pregnant or lactating (pregnancy is defined as the state after conception and until the termination of gestation);\n* Subjects of childbearing potential who are pregnant or planning to donate sperm\u002Fova or are unwilling to take highly effective contraceptive measures from the signing of the informed consent form to 20 weeks (5 half-lives) after the use of the investigational product;\n* History of alcohol or illicit drug abuse within one year prior to screening;\n* Any other condition that, in the opinion of the investigator, would prevent the subject from following and completing the study protocol or interfere with the study analysis.","ALL","18 Years","75 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Randomized trial aimed to assess in adults with PsA the effect of oral CBP-0276 administrated at a dose of 200mg QD, or 800mg QD vs. Placebo for CBP-0276 for 24 weeks. Primary outcome is the change at least 20% on severity of symptoms eat week 24, using the American College Rheumatologic Score (ACR) and key secondary outcomes are the change on ACR20% at week 16 and ACR50\u002F70% at week 24. Eligible patients will be randomly assigned (1:1:1) to receive oral CBP-0276 200mg QD, 800mg QD or placebo for CBP-0276 for 24 weeks",[27],"Arthritic Psoriasis",[29],"arthritic psoriasis adults","NOT_YET_RECRUITING","2026-07-14",{"date":33,"type":34},"2026-07-16","ACTUAL",{"date":36,"type":21},"2026-07",{"date":38,"type":21},"2027-03",{"name":40,"class":41},"Clarent Biopharma, Inc.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":18,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":42},"100646769","phase-2-cbp-0276-to-reduce-opioid-use-in-adults-undergoing-major-orthopedic-surgery-100646769","NCT07687966","CBP-0276 to Reduce Opioid Use in Adults Undergoing Major Orthopedic Surgery","Proof-of-concept, Double-blind, Randomized Clinical Study to Evaluate the Safety and Efficacy of CBP-0276 at Doses of 600 mg\u002FDay vs Placebo in Reducing Opioid Use in Pain Management in Adult Patients Undergoing Major Orthopedic Surgery","CBP0276-Opd","Inclusion criteria:\n\n* Men or women\n* Age between 40 and 75 years (inclusive)\n* Body weight between 50 and 90 Kg\n* Post-surgical patient of major orthopedic surgery, with opioid treatment (oxycodone) at discharge by treating physician\n* Physical status of ASA I to III\n* Be able and willing to read, understand, sign, and date the Informed\n* Consent Form prior to entering the study.\n* Woman of childbearing age with effective contraception, not pregnant, not on breastfeeding, not pregnancy plans during the development of the study, postmenopausal, defined by cessation of menstruation for at least 12 consecutive months and confirmed by serum FSH levels \\> 40 mIU\u002FmL and estradiol \\\u003C 20 pg\u002FmL or surgically sterile (with hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) and not undergoing in vitro fertilization or other fertility treatments)\n* Men agreed to use contraception or remain abstinent (when this is the subject's usual and preferred lifestyle)Be willing to complete all study visits and procedures.\n\nExclusion criteria:\n\n* History of respiratory depression, severe bronchial asthma, chronic obstructive pulmonary disease, or acute and\u002For severe hypercepnia and cor pulmonale.\n* History of gastrointestinal motility disorders (e.g., severe reflux esophagitis, gastroparesis, severe irritable bowel syndrome, active inflammatory bowel disease, and paralytic ileus).\n* History of depression, seizures, and epilepsy.\n* Uncontrolled hypertension: systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg confirmed by at least two measurements.\n* History of allergic reactions, anaphylactic reactions, severe systemic hypersensitivity, or any allergic reaction that, in the opinion of the Principal Investigator or his \u002Fher delegate, is likely to be exacerbated by the study drug (RAP-103 and oxycodone).\n* History of human immunodeficiency virus or positive HIV test result (HIV 1-2 antibodies).\n* History of hepatitis C infection or positive hepatitis C virus (HCVAb) antibody screening result.\n* Current hepatitis B (HBV) infection (defined as positive for HepBsAg and\u002For HepBcAb). Subjects with immunity to hepatitis B from prior natural infection (defined as HepBsAg negative, HepBcAb positive, and HepBsAb positive) or vaccination (defined as HepBsAg negative, HepBCAb negative, and HepBSAb positive) are eligible to participate in the study.\n* Transcutaneous oxygen saturation (SpO₂) \\\u003C90%.\n* Patients with severe liver or kidney disease.\n* Patients with immunosuppression, neoplasms, or HIV infection.\n* Active substance use disorder (SUD) or within the previous 12 months, including opioid, alcohol, benzodiazepines, or any other substance with potential for abuse.\n* Patients with the use of antipsychotic medications.\n* Any clinical condition that makes it difficult to self-assess pain.\n* Recent opioid use (14 days prior recruitment).\n* Previous exposure to RAP-103 or DAPTA (T-Peptide) at any time in your life.\n* Abnormal and clinically significant results at the discretion of the Principal investigator (or his\u002Fher delegate) in the laboratory tests and electrocardiogram of visit 0. Laboratory values out of range and determined to be not clinically significant at the discretion of the Principal Investigator or his\u002Fher delegate may be repeated on one occasion, the subject may be enrolled if the repeated value is within the normal range.\n* Participation in any other investigational study with drugs, biologics, medical devices, or treatment with an investigational product or therapy approved for investigational use within 30 days or 5 halflives at visit 0.\n* Any other condition that, in the judgment of the PI or Sponsor, determines that the subject is not suitable to participate in the study.","40 Years",{"count":53,"type":21},80,[24],"Randomized, double-blind, clinical study to evaluate the safety and efficacy of CBP-0276 at doses of 600 mg\u002Fday in reducing opioid use in pain management in adult patients undergoing major orthopedic surgery. Subjects will be allocated in 2 groups. One group will receive oxycodone (standard of care) + CBP-0276 at a dose of 600 mg, orally once daily for 28 days. A second group will receive oxycodone (standard of care) + placebo for CBP-0276, orally once daily for 28 days",[57],"Hip or Knee Replacement","RECRUITING","2026-07-02",{"date":61,"type":34},"2026-07-07",{"date":63,"type":34},"2026-05-08",{"date":65,"type":21},"2026-09-30",{"name":40,"class":41},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":42},"100608675","phase-2-safety-and-efficacy-of-cbp-0276-to-improve-severity-and-quality-of-life-on-moderate-to-severe-psoriasis-in-subjects-100608675","NCT07204639","Safety and Efficacy of CBP-0276 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects","Safety and Efficacy of CBP-0276 200mg\u002FDay Twice Dose a Day, or Placebo Administrated for 36 Weeks, to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects 18y to 70y: Randomized Controlled Trial","CBP-0276-Pso","Inclusion Criteria:\n\n1. Signed written informed consent\n\n   a. Patients must be willing to participate in the study and sign the informed consent form\n2. Type of patient and target disease characteristics\n\n   1. Men and women, diagnosed with stable plaque psoriasis for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity, in the opinion of the investigator\n   2. Deemed by the investigator to be a candidate for systemic therapy\n   3. ≥10% of body surface area (BSA) involvement at screening visit and Day 1\n   4. Psoriasis Area and Severity Index (PASI) score ≥12, and static Physician's Global Assessment (sPGA) ≥3 at screening visit and Day 1\n3. Age and reproductive status\n\n   1. Men and women aged 18 years to 70 years at the time of screening visit\n   2. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening visit, and a negative urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin within 24 hours prior to the start of study drug\n   3. Women must not be pregnant, lactating, breastfeeding, or planning pregnancy during the study period\n   4. Women of childbearing potential must agree to correctly use a highly effective method(s) of contraception for the duration of treatment plus 30 days (duration of ovulatory cycle) for a total of 33 days post-treatment completion (total of 33 days after last dose of study drug). WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements, but must still undergo pregnancy testing as described in this protocol\n   5. Male patients who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study treatment(s) plus 5 half-lives of the study treatment (3 days) for a total of 3 days post-treatment completion.\n\n      Additionally, male patients must be willing to refrain from sperm donation during this time\n   6. Investigators shall counsel WOCBP, and male patients who are sexually active with WOCBP, on the importance of pregnancy prevention and the implications of an unexpected pregnancy. Investigators shall advise on the use of highly effective methods of contraception, which have a failure rate of \\\u003C1% when used consistently and correctly.\n\nExclusion Criteria:\n\n1. Use of phototherapy 4 weeks or less prior randomization\n2. Infectious\u002Fimmune-related exclusions\n\n   1. History or evidence of outpatient active infection and\u002For febrile illness within 7 days prior to Day 1\n   2. History of serious bacterial, fungal, or viral infection requiring hospitalization and intravenous antimicrobial treatment within 60 days prior to Day 1\n   3. Any untreated bacterial infection within 60 days prior to Day 1\n   4. Any ongoing evidence of chronic bacterial infection (eg, chronic pyelonephritis, chronic osteomyelitis, chronic bronchiectasis)\n   5. Any history of proven infection of a joint prosthesis in which the prosthesis was not removed or replaced, or received antibiotics for suspected infection of a joint prosthesis in which the prosthesis was not removed or replaced\n   6. Received live vaccines within 60 days prior to Day 1, or plans to receive a live vaccine during the study, or within 60 days after completing study treatment\n   7. Presence of herpes zoster lesions at screening or Day 1\n   8. History of serious herpes zoster or serious herpes simplex infection, which includes, but is not limited to, any episode of disseminated herpes simplex, multidermatomal herpes zoster, herpes encephalitis, ophthalmic herpes, or recurrent herpes zoster (recurrent is defined as 2 episodes within 2 years)\n   9. Evidence of, or positive test for, hepatitis B virus at screening. Positive hepatitis B lab testing is defined as 1) positive hepatitis B surface antigen (HBsAg+) OR 2) presence of hepatitis B virus DNA OR 3) positive anti-hepatitis B core antibody without concurrent positive hepatitis B surface antibody (HBcAb+ and HBsAb-)\n   10. Evidence of, or positive test for, hepatitis C virus (HCV) at screening. A positive test for HCV is defined as: positive for hepatitis C antibody (anti-HCV Ab) AND 2) positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction)\n   11. Positive for human immunodeficiency virus by antibody testing (HIV-1 and -2 Ab) at screening\n   12. Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the patient's immune status (eg, history of opportunistic infections \\[eg, Pneumocystis jirovecii pneumonia, histoplasmosis, or coccidioidomycosis\\], history of splenectomy, primary immunodeficiency)\n3. Any of the following tuberculosis (TB) criteria:\n\n   1. History of active TB prior to screening visit, regardless of completion of adequate treatment\n   2. Signs or symptoms of active TB (eg, fever, cough, night sweats, and weight loss) during screening, as judged by the investigator\n   3. Any imaging of the chest (eg, chest x-ray, chest computed tomography scan) obtained during the screening period, or any time within 6 months prior to screening with documentation, showing evidence of current active or history of active pulmonary TB\n   4. Latent TB infection (LTBI) defined as positive interferon gamma release assay (IGRA), by QuantiFERON-TB Gold testing at screening, in the absence of clinical manifestations\n\n   Note: Patient is eligible if (i) there are no current signs or symptoms of active TB AND (ii) patient has received adequate documented treatment for LTBI within 5 years of screening OR has initiated prophylactic treatment for LTBI per local guidelines and is rescreened after 1 month of treatment. To continue in the study, patient must agree to complete a locally recommended course of treatment for LTBI. Use of rifampin, however, is not recommended as it can reduce efficacy of apremilast used as a comparator in this trial\n\n   Note: An IGRA test that is indeterminate must be retested for confirmation. If the second test is again indeterminate, the patient will be excluded from the study. If the retest is positive, the patient should be treated as having LTBI. If the retest is negative, the patient may be eligible provided no other exclusion criteria for TB are met.\n4. Medical history and concurrent diseases\n\n   1. Any major surgery within 8 weeks prior to Day 1, or any planned surgery for the first 52 weeks of the study\n   2. Has donated blood \\>500 mL within 4 weeks prior to Day 1, or plans to donate blood during the course of the study\n   3. Drug or alcohol abuse, as determined by the investigator, within 6 months prior to Day 1\n   4. Medical marijuana or prescription marijuana taken for medicinal reasons\n   5. Any major illness\u002Fcondition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, psychiatric, neurologic, immunologic, or local active infection\u002Finfectious illness) that, in the investigator's judgment or after consultation with the medical monitor, will substantially increase the risk to the patient if he or she participates in the study\n   6. Unstable cardiovascular disease, defined as a recent clinical cardiovascular event (eg, unstable angina, myocardial infarction, stroke, rapid atrial fibrillation) in the last 3 months prior to screening, or a cardiac hospitalization (eg, revascularization procedure, pacemaker implantation) within 3 months prior to screening\n   7. Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) \\>160 mm Hg or diastolic BP \\>100 mm Hg\n\n      Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this limit, the BP may be repeated once after the patient has rested sitting for ≥10 minutes. If the repeat value is less than the criterion limits, the second value may be accepted.\n   8. Class III or IV congestive heart failure by New York Heart Association Criteria\n   9. Has cancer or history of cancer (solid organ or hematologic including myelodysplastic syndrome) or lymphoproliferative disease within the previous 5 years (other than resected cutaneous basal cell or squamous cell carcinoma, or carcinoma of cervix in situ that has been treated with no evidence of recurrence)\n   10. Any uncontrolled psychiatric illness (such as untreated depression, or bipolar disorder) judged as clinically significant by the investigator during screening or at Day 1 OR any lifetime history of suicidal ideation, suicidal behavior, or suicidal attempts by medical history or by electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) documentation, or by answering \"yes\" to Question 4 or 5 for suicidal ideation on the eC-SSRS at screening or at Day 1, or is clinically deemed to have a suicide risk by the investigator\n   11. Prior exposure to investigational product on the last 6 months (ie, deucravacitinib or apremilast)\n   12. If the patient has received biologics previously, the following exclusion criteria for washout will apply: Antibodies to IL-12, IL-17, or IL-23 within 6 months of Day 1 prior randomization; Tumor necrosis factor inhibitor(s) within 2 months of Day 1; Agents that modulate integrin pathways to impact lymphocyte trafficking (eg, natalizumab), or agents that modulate B cells or T cells within 3 months of Day 1; or Rituximab within 6 months of Day 1\n   13. Has received systemic nonbiologic psoriasis medications and\u002For any systemic immunosuppressant therapy, including, but not limited to methotrexate, azathioprine, cyclosporine, Janus kinase inhibitors, mercaptopurine, mycophenolate mofetil, tacrolimus, oral or injectable corticosteroids, retinoids, 1,25-dihydroxy vitamin D3 and analogues within 4 weeks prior to Day 1\n   14. Has used leflunomide within 6 months prior to Day 1\n   15. Has used opioid analgesics within 4 weeks prior to Day 1\n   16. Has received lithium, antimalarials, or intramuscular gold within 4 weeks of the first administration of any study medication\n   17. Has used any strong CYP450 inducers (eg, rifampin, phenobarbital, carbamazepine, phenytoin) within 4 weeks prior to Day 1\n   18. Has used topical medications\u002Ftreatments that could affect psoriasis evaluation (including, but not limited to, high potency corticosteroids (World Health Organization \\[WHO\\] Classes I-V), \\>3% salicylic acid, urea, alpha- or beta-hydroxyl acids, anthralin, calcipotriene, topical vitamin D derivatives, retinoids, tazarotene, methoxsalen, pimecrolimus, and tacrolimus) within 2 weeks prior to Day 1\n\n       Note: Low-potency topical steroids (WHO Class VI and VII) are permitted on the palms, soles, face, and intertriginous areas but should not be used within 24 hours prior to any study visit. Bland emollients (defined as emollients without urea or alpha or beta hydroxy acids or other ingredients that are pharmaceutically active) are allowed on all body regions but should not be used within 24 hours prior to any study visit.\n   19. Use of shampoos containing corticosteroids, coal tar, \\>3% salicylic acid, or vitamin D3 analogues within 2 weeks prior to Day 1\n   20. Has received an experimental antibody or experimental biologic therapy within the previous 6 months OR received any other experimental therapy or new investigational agent within 30 days or 5 half-lives (whichever is longer) prior to Day 1 OR is currently enrolled in an investigational study\n5. Laboratory evaluations\n\n   1. Absolute white blood cell count \\\u003C3000\u002Fmm3\n   2. Absolute lymphocyte count \\\u003C500\u002Fmm3\n   3. Absolute neutrophil count \\\u003C1000\u002Fmm3\n   4. Platelet count \\\u003C100,000\u002Fmm3\n   5. Hemoglobin \\\u003C9 g\u002FdL\n   6. Alanine aminotransferase and\u002For aspartate aminotransferase \\>3 × upper limit of normal (ULN)\n   7. Total, unconjugated, and\u002For conjugated bilirubin \\>2 × ULN\n   8. Thyroid-stimulating hormone outside the normal reference range AND free T4 (thyroxine) or T3 (triiodothyronine) outside the normal reference range\n   9. Electrocardiogram abnormalities that are considered clinically significant and would pose an unacceptable risk to the patient if participating in the study\n   10. Renal impairment based on an estimated glomerular filtration rate \\\u003C45 mL\u002Fmin","70 Years",{"count":77,"type":21},100,[24],"Randomized, controlled trial, Proof of Concept, Phase 2 aimed to evaluate the effect of CBP-0276 in dose of 200mg twice dose a day, or placebo administrated for 36 weeks to improve Psoriasis Area and Severity Index (PASI)75 or static Physician's Global Assessment (sPGA) score of 0 or 1; PASI50, PASI90, PASI100, Scalp-specific Physician's Global Assessment (Ss-PGA) 0\u002F1 with at least a 2-point improvement among patients with a baseline ss-PGA ≥3, sPGA 0, PSSD symptom score of 0 among patients with baseline score ≥1, Dermatology Life Quality Index (DLQI) 0\u002F1 at Week 6,12,18,24, 30 and 36 among patients with baseline DLQI ≥2, adjusted by transcriptomics profile (post-hoc analysis), Percentage of subjects which achieve The Minimum Clinically Important Difference (MCID) on DLQI (a ≥4-point reduction from baseline) at Week 4 and 8, Frequency of solicited and unsolicited adverse events (SAEs and USAEs) (Medra), and Changes on inflammatory and anti-inflammatory cytokine levels during treatment (IL-17, IL-23, IL-6, TNF-alpha, IL1-b, IL-10).",[81],"Psoriasis",[83],"CBP-0276, Randomized trial phase 2, Psoriasis","2026-06-26",{"date":86,"type":34},"2026-06-30",{"date":88,"type":34},"2025-10-01",{"date":90,"type":21},"2026-08-30",{"name":40,"class":41},""]